Is TG Therapeutics Stock a Good Investment?
TG Therapeutics Investment Advice | TGTX |
- Examine TG Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research TG Therapeutics' leadership team and their track record. Good management can help TG Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact TG Therapeutics' business and its evolving consumer preferences.
- Compare TG Therapeutics' performance and market position to its competitors. Analyze how TG Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if TG Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about TG Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in TG Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if TG Therapeutics is a good investment.
Sell | Buy |
Hold
Market Performance | OK | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Very Low | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine TG Therapeutics Stock
Researching TG Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 63.0% of the company shares are owned by institutional investors. The company had not issued any dividends in recent years. TG Therapeutics had 100:5625 split on the 30th of April 2012.
To determine if TG Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding TG Therapeutics' research are outlined below:
| TG Therapeutics appears to be risky and price may revert if volatility continues | |
| TG Therapeutics currently holds about 195.71 M in cash with (40.52 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.45. | |
| TG Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 63.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Opaleye Management Inc. Adjusts Stake in Harrow Inc. |
TG Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in TG Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to TG Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 6th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact TG Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises TG Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-04 | 2024-09-30 | 0.03 | 0.02 | -0.01 | 33 | ||
2014-03-05 | 2013-12-31 | -0.17 | -0.19 | -0.02 | 11 | ||
2013-05-14 | 2013-03-31 | -0.15 | -0.17 | -0.02 | 13 | ||
2024-05-01 | 2024-03-31 | -0.04 | -0.07 | -0.03 | 75 | ||
2012-11-08 | 2012-09-30 | -0.12 | -0.16 | -0.04 | 33 | ||
2017-11-08 | 2017-09-30 | -0.43 | -0.48 | -0.05 | 11 | ||
2016-08-08 | 2016-06-30 | -0.28 | -0.33 | -0.05 | 17 | ||
2016-03-07 | 2015-12-31 | -0.32 | -0.37 | -0.05 | 15 |
TG Therapeutics Target Price Consensus
TGTX target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. TG Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 9 | Strong Buy |
Most TGTX analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand TGTX stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of TG Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationTG Therapeutics Target Price Projection
TG Therapeutics' current and average target prices are 42.99 and 40.88, respectively. The current price of TG Therapeutics is the price at which TG Therapeutics is currently trading. On the other hand, TG Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
TG Therapeutics Market Quote on 22nd of March 2025
Target Price
Analyst Consensus On TG Therapeutics Target Price
TG Therapeutics Analyst Ratings
TG Therapeutics' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about TG Therapeutics stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of TG Therapeutics' financials, market performance, and future outlook by experienced professionals. TG Therapeutics' historical ratings below, therefore, can serve as a valuable tool for investors.Know TG Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as TG Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading TG Therapeutics backward and forwards among themselves. TG Therapeutics' institutional investor refers to the entity that pools money to purchase TG Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Goldman Sachs Group Inc | 2024-12-31 | 1.6 M | Northern Trust Corp | 2024-12-31 | 1.5 M | Hood River Capital Management Llc | 2024-12-31 | 1.5 M | Charles Schwab Investment Management Inc | 2024-12-31 | 1.3 M | Fmr Inc | 2024-12-31 | 1 M | Amvescap Plc. | 2024-12-31 | 929.7 K | Bank Of New York Mellon Corp | 2024-12-31 | 923.5 K | Principal Financial Group Inc | 2024-12-31 | 830.2 K | Susquehanna International Group, Llp | 2024-12-31 | 827.1 K | Blackrock Inc | 2024-12-31 | 21.9 M | Vanguard Group Inc | 2024-12-31 | 15.6 M |
TG Therapeutics' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 6.75 B.Market Cap |
|
TG Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.04 | 0.04 | |
| Return On Capital Employed | 0.09 | 0.07 | |
| Return On Assets | 0.04 | 0.04 | |
| Return On Equity | 0.11 | 0.11 |
Determining TG Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if TG Therapeutics is a good buy. For example, gross profit margin measures TG Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of TG Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in TG Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of TG Therapeutics. Check TG Therapeutics' Beneish M Score to see the likelihood of TG Therapeutics' management manipulating its earnings.
Evaluate TG Therapeutics' management efficiency
TG Therapeutics has return on total asset (ROA) of 0.0578 % which means that it generated a profit of $0.0578 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1222 %, meaning that it created $0.1222 on every $100 dollars invested by stockholders. TG Therapeutics' management efficiency ratios could be used to measure how well TG Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, TG Therapeutics' Return On Tangible Assets are fairly stable compared to the past year. Return On Assets is likely to rise to 0.04 in 2025, whereas Return On Capital Employed is likely to drop 0.07 in 2025. At this time, TG Therapeutics' Total Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 594.7 M in 2025, whereas Non Current Assets Total are likely to drop slightly above 7.6 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.53 | 1.45 | |
| Tangible Book Value Per Share | 1.53 | 1.45 | |
| Enterprise Value Over EBITDA | 89.13 | 93.59 | |
| Price Book Value Ratio | 19.67 | 20.65 | |
| Enterprise Value Multiple | 89.13 | 93.59 | |
| Price Fair Value | 19.67 | 20.65 | |
| Enterprise Value | 4.4 B | 4.7 B |
Understanding the operational decisions made by TG Therapeutics management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Beta 2.301 |
Basic technical analysis of TGTX Stock
As of the 22nd of March, TG Therapeutics owns the Downside Deviation of 3.08, mean deviation of 2.93, and Risk Adjusted Performance of 0.123. In connection with fundamental indicators, the technical analysis model makes it possible for you to check timely technical drivers of TG Therapeutics, as well as the relationship between them.TG Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific TG Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on TG Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases TG Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
TG Therapeutics' Outstanding Corporate Bonds
TG Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. TG Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most TGTX bonds can be classified according to their maturity, which is the date when TG Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| TOPTB 35 17 OCT 49 Corp BondUS88323AAE29 | View | |
| TOPTB 5375 20 NOV 48 Corp BondUS88323AAD46 | View | |
| TOPTB 375 18 JUN 50 Corp BondUS88323AAH59 | View | |
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| TEXTRON INC 3375 Corp BondUS883203BY60 | View |
Understand TG Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing TG Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.123 | |||
| Market Risk Adjusted Performance | 0.9401 | |||
| Mean Deviation | 2.93 | |||
| Semi Deviation | 2.74 | |||
| Downside Deviation | 3.08 | |||
| Coefficient Of Variation | 770.01 | |||
| Standard Deviation | 4.05 | |||
| Variance | 16.41 | |||
| Information Ratio | 0.144 | |||
| Jensen Alpha | 0.5535 | |||
| Total Risk Alpha | 0.8238 | |||
| Sortino Ratio | 0.1892 | |||
| Treynor Ratio | 0.9301 | |||
| Maximum Drawdown | 18.67 | |||
| Value At Risk | (4.98) | |||
| Potential Upside | 7.64 | |||
| Downside Variance | 9.52 | |||
| Semi Variance | 7.52 | |||
| Expected Short fall | (3.72) | |||
| Skewness | 0.8955 | |||
| Kurtosis | 1.52 |
| Risk Adjusted Performance | 0.123 | |||
| Market Risk Adjusted Performance | 0.9401 | |||
| Mean Deviation | 2.93 | |||
| Semi Deviation | 2.74 | |||
| Downside Deviation | 3.08 | |||
| Coefficient Of Variation | 770.01 | |||
| Standard Deviation | 4.05 | |||
| Variance | 16.41 | |||
| Information Ratio | 0.144 | |||
| Jensen Alpha | 0.5535 | |||
| Total Risk Alpha | 0.8238 | |||
| Sortino Ratio | 0.1892 | |||
| Treynor Ratio | 0.9301 | |||
| Maximum Drawdown | 18.67 | |||
| Value At Risk | (4.98) | |||
| Potential Upside | 7.64 | |||
| Downside Variance | 9.52 | |||
| Semi Variance | 7.52 | |||
| Expected Short fall | (3.72) | |||
| Skewness | 0.8955 | |||
| Kurtosis | 1.52 |
Consider TG Therapeutics' intraday indicators
TG Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of TG Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
TG Therapeutics Corporate Filings
F4 | 18th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 3rd of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 8th of January 2025 Other Reports | ViewVerify | |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
TGTX Stock media impact
Far too much social signal, news, headlines, and media speculation about TG Therapeutics that are available to investors today. That information is available publicly through TGTX media outlets and privately through word of mouth or via TGTX internal channels. However, regardless of the origin, that massive amount of TGTX data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of TG Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of TG Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to TG Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive TG Therapeutics alpha.
TG Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards TG Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
TG Therapeutics Historical Investor Sentiment
Investor biases related to TG Therapeutics' public news can be used to forecast risks associated with an investment in TGTX. The trend in average sentiment can be used to explain how an investor holding TGTX can time the market purely based on public headlines and social activities around TG Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
TG Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for TG Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average TG Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on TG Therapeutics.
TG Therapeutics Maximum Pain Price Across May 16th 2025 Option Contracts
TG Therapeutics' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of TG Therapeutics close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of TG Therapeutics' options.
TG Therapeutics Corporate Executives
Elected by the shareholders, the TG Therapeutics' board of directors comprises two types of representatives: TG Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of TGTX. The board's role is to monitor TG Therapeutics' management team and ensure that shareholders' interests are well served. TG Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, TG Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Additional Tools for TGTX Stock Analysis
When running TG Therapeutics' price analysis, check to measure TG Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TG Therapeutics is operating at the current time. Most of TG Therapeutics' value examination focuses on studying past and present price action to predict the probability of TG Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TG Therapeutics' price. Additionally, you may evaluate how the addition of TG Therapeutics to your portfolios can decrease your overall portfolio volatility.